ReviewJournal of clinical medicine2025
Atrial Fibrillation and Cancer: Pathophysiological Mechanism and Clinical Implications.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Incidence of new-onset atrial fibrillation after thoracic radiotherapy in non-small cell lung cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Atrial fibrillation secondary to diffuse large B-cell lymphoma responding to corticosteroid treatment: a case report.European heart journal. Case reports · 2026Article
- Neoplastic Disorders and Cardiovascular Comorbidities in Geriatric Patients: A Simple Association?Geriatrics (Basel, Switzerland) · 2026Review
- Clinical Impact of Semaglutide Beyond Glycemic Control: A Critical Analysis of Oncogenic Potential and Mitigation of Cardiotoxicity.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Immune Checkpoint Inhibitor-Associated Myocarditis: Risk, Diagnosis, and Clinical Impact.Journal of clinical medicine · 2026Review
- Pediatric Cardio-Oncology: From Gap in Evidence to Future Perspectives.Diagnostics (Basel, Switzerland) · 2026Review
- Protective Role of Lipid-Lowering Drugs in Breast Cancer: Effects on Cancer Incidence and Cardiotoxicity.Life (Basel, Switzerland) · 2025Review
- Takotsubo Syndrome and Cancer: Pathophysiological Links and Clinical Perspectives.Biomedicines · 2025Review
- The Crucial Role of Tinzaparin in Managing Venous Thromboembolism in the Cancer Population.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation is the most frequent arrhythmia in elderly subjects. Cancer currently represents one of the most important causes of mortality and morbidity in the world. Often, the two pathologies coexist. Several pathophysiological mechanisms can lead to an increased risk of atrial fibrillation and cancer. Additionally, the same therapies used for cancer can increase the risk of developing atrial fibrillation. Our review aims to describe the pathophysiological mechanisms that promote the development of atrial fibrillation in cancer patients and explain the therapeutic opportunities and challenges of treating atrial fibrillation in patients with cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.